Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

類似資料

• Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
  著者:: Hirashima, Tomonori, 等
  出版事項: (2019)
• Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples
  著者:: Kiura, Katsuyuki, 等
  出版事項: (2018)
• Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
  著者:: Ohe, Yuichiro, 等
  出版事項: (2018)
• Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
  著者:: Tokudome, Nahomi, 等
  出版事項: (2020)
• Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
  著者:: Sakai, Kazuko, 等
  出版事項: (2020)